| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation MR Patel, KW Mahaffey, J Garg, G Pan, DE Singer, W Hacke, G Breithardt, ... New England Journal of Medicine 365 (10), 883-891, 2011 | 12046 | 2011 |
| Oral rivaroxaban for symptomatic venous thromboembolism E Investigators New England Journal of Medicine 363 (26), 2499-2510, 2010 | 3968 | 2010 |
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism Einstein–PE Investigators New England journal of medicine 366 (14), 1287-1297, 2012 | 2931 | 2012 |
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial AGG Turpie, MR Lassen, BL Davidson, KA Bauer, M Gent, LM Kwong, ... The Lancet 373 (9676), 1673-1680, 2009 | 1373 | 2009 |
| Rivaroxaban for stroke prevention after embolic stroke of undetermined source RG Hart, M Sharma, H Mundl, SE Kasner, SI Bangdiwala, SD Berkowitz, ... New England Journal of Medicine 378 (23), 2191-2201, 2018 | 1016 | 2018 |
| Rivaroxaban in peripheral artery disease after revascularization MP Bonaca, RM Bauersachs, SS Anand, ES Debus, MR Nehler, MR Patel, ... New England Journal of Medicine 382 (21), 1994-2004, 2020 | 858 | 2020 |
| Rivaroxaban or aspirin for extended treatment of venous thromboembolism JI Weitz, AWA Lensing, MH Prins, R Bauersachs, J Beyer-Westendorf, ... New England Journal of Medicine 376 (13), 1211-1222, 2017 | 854 | 2017 |
| Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia BE Lewis, DE Wallis, SD Berkowitz, WH Matthai, J Fareed, JM Walenga, ... Circulation 103 (14), 1838-1843, 2001 | 847 | 2001 |
| Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies MH Prins, AWA Lensing, R Bauersachs, B Van Bellen, H Bounameaux, ... Thrombosis journal 11, 1-10, 2013 | 679 | 2013 |
| Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. JA Dent, SD Berkowitz, J Ware, CK Kasper, ZM Ruggeri Proceedings of the National Academy of Sciences 87 (16), 6306-6310, 1990 | 459 | 1990 |
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ... The Lancet 391 (10117), 205-218, 2018 | 415 | 2018 |
| Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement CW Francis, SD Berkowitz, PC Comp, JR Lieberman, JS Ginsberg, ... New England Journal of Medicine 349 (18), 1703-1712, 2003 | 411 | 2003 |
| Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial JN Fiessinger, MV Huisman, BL Davidson, H Bounameaux, CW Francis, ... Jama 293 (6), 681-689, 2005 | 404 | 2005 |
| Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty AGG Turpie, MR Lassen, BI Eriksson, M Gent, SD Berkowitz, F Misselwitz, ... Thrombosis and haemostasis 105 (03), 444-453, 2011 | 386 | 2011 |
| Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial BA Steinberg, AS Hellkamp, Y Lokhnygina, MR Patel, G Breithardt, ... European heart journal 36 (5), 288-296, 2015 | 382 | 2015 |
| Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF HE Gerritsen, PL Turecek, HP Schwarz, B Lämmle, M Furlan Thrombosis and haemostasis 82 (11), 1386-1389, 1999 | 364 | 1999 |
| Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a … MH Prins, AWA Lensing, TA Brighton, RM Lyons, J Rehm, M Trajanovic, ... The Lancet Haematology 1 (1), e37-e46, 2014 | 333 | 2014 |
| Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction SD Berkowitz, CB Granger, KS Pieper, KL Lee, JM Gore, M Simoons, ... Circulation 95 (11), 2508-2516, 1997 | 293 | 1997 |
| Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for … SG Goodman, DM Wojdyla, JP Piccini, HD White, JF Paolini, CC Nessel, ... Journal of the American College of Cardiology 63 (9), 891-900, 2014 | 287 | 2014 |
| Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy SD Berkowitz, RA Harrington, MM Rund, JE Tcheng Circulation 95 (4), 809-813, 1997 | 271 | 1997 |
